Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus (ATLAS2)
Staphylococcal Skin Infection
About this trial
This is an interventional treatment trial for Staphylococcal Skin Infection focused on measuring cSSSI (complicated Skin and Skin Structure Infections), Staph (Staphylococcus), MRSA (Methicillin-resistant Staphylococcus Aureus)
Eligibility Criteria
Inclusion Criteria: Patients must have a diagnosis of one of the following complicated skin and skin structure infections with MRSA (Methicillin-resistant Staphylococcus Aureus) either suspected or confirmed as the major cause of the infection: major abscess requiring surgical incision and drainage; infected burn (see exclusion criteria for important qualifications); deep/extensive cellulitis; infected ulcer (see exclusion criteria for important qualifications); wound infections Patients must be expected to require at least 7 days of intravenous antibiotic treatment. Exclusion Criteria: Received more than 24 hours of potentially effective systemic (IV/IM or PO) antibiotic therapy Burns involving > 20% of body surface area or third degree/full thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fasciitis, gas gangrene, or mediastinitis.
Sites / Locations
- Louisiana State University Health Sciences Center, Dept of Med/ER Med
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Telavancin
Vancomycin